The UK has the highest prevalence of mesothelioma worldwide and incidence is increasing and predicted to peak in 2015-2025. The UK also has the highest death rate from malignant mesothelioma in the world accounting for 1 in 170 deaths. Patients with mesothelioma are well recognised to have a significant burden of symptoms.This UK multi-centre randomised controlled trial seeks to examine the effect of regular early specialist palliative care on quality of life and mood of patients diagnosed with malignant pleural mesothelioma, their carer’s quality of life and mood, and cost-effectiveness to the healthcare system. RESPECT-Meso has been peer reviewed through a competitive process and awarded a grant through the British Lung Foundation (grant ref: APG12-13). The aspiration is that this research may be of significant benefit to patients and their carer’s. We will recruit 174 patients to this study. What are the benefits to your centre in participating in this study?Aside from the recognised positive public impression of centres and Trusts that participate in research, as his study has been adopted to the comprehensive local research network (CLRN) portfolio there is a clear remuneration package involved. The activity based funding model outlined in 2010/11 CRN budget and agreed by the Department of Health dictates that each participant randomised to this study would generate an income of £ 1,509 for the participating centre. As this study also involves randomising the patient’s primary caregiver in addition, this is considered to be a further separate participant and attracts the same tariff. Therefore, for each patient / carer pair randomised a participating centre will generate an income of £3,018 for your centre.What are the main resource implications for participating sites?We will need participating centres to recruit at least one patient per month to the study. We think this is realistic and achievable. After recruitment, the patients will need to be followed up with a clinic visit (three and six months) or telephone consultation (months 1,2,4,5) to complete the quality of life questionnaires and other relevant study information (approx 20 mins each). This could either be from a dedicated research nurse, or though clinical teams if resources permit. The study intervention will be regular early specialist palliative care. Patients in the intervention arm will receive 4 weekly outpatient appointments with the specialist palliative care (SPC) team until end of trial of patient death. The first appointment may take up to an hour (with a nurse), after that it will be routine follow up times (20-30 mins).
A study to learn more about treating malignant mesothelioma - can we improve quality of life?